DOCSLIB.ORG

Safety Assessment of Hydrofluorocarbon 152A As Used in Cosmetics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Safety Assessment of Hydrofluorocarbon 152A As Used in Cosmetics Safety Assessment of Hydrofluorocarbon 152a as Used in Cosmetics Status: Tentative Report for Public Comment Release Date: October 7, 2016 Panel Meeting Date: April 10-11, 2017 All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill. The 2016 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Christina Burnett, Senior Scientific Analyst/Writer. Cosmetic Ingredient Review 1620 L Street NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] ABSTRACT The Cosmetic Ingredient Review (CIR) Expert Panel (the Panel) reviewed the safety of Hydrofluorocarbon 152a, which functions as a propellant in personal care products. The Panel reviewed relevant data provided in this safety assessment, and concluded that Hydrofluorocarbon 152a is safe in the present practices of use and concentration described in this safety assessment. INTRODUCTION Hydrofluorocarbon 152a is a gas that functions as a propellant in personal care products, according to the International Cosmetic Dictionary and Handbook.1 It is commonly known as 1,1-difluoroethane. CHEMISTRY Definition Hydrofluorocarbon 152a (CAS No. 75-37-6) is the halocarbon, 1,1-difluoroethane, that conforms to the 1 formula CH3CHF2. Figure 1. Hydrofluorocarbon 152a Chemical and Physical Properties Hydrofluorocarbon 152a is a colorless, odorless gas, with a vapor pressure of 4550 mmHg at 25 oC. This ingredient is distinct from chlorofluorocarbon propellants, such as Hydrochlorofluorocarbon 142b, because there are no chlorine atoms to react with stratospheric ozone. Additional physical and chemical properties of Hydrofluorocarbon 152a are provided in Table 1. Method of Manufacturing Hydrofluorocarbon 152a may be derived by reacting hydrogen fluoride with acetylene.2 The material may also be produced by a catalytic reaction of vinyl chloride with hydrofluoric acid, in a closed system.3 Impurities Hydrofluorocarbon 152a is reported to be greater than 99.9% pure.3 Impurities may include water, residual hydrochloric acid, and residual hydrofluoric acid. USE Cosmetic The safety of the cosmetic ingredient included in this assessment is evaluated based on data received from the U.S. Food and Drug Administration (FDA) and the cosmetics industry on the expected use of this ingredient in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in FDA’s Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by Industry in response to surveys, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category. According to 2016 VCRP data, Hydrofluorocarbon 152a is used in 372 formulations; the majority of uses are in leave-on hair care products (Table 2).4 The results of the concentration of use survey conducted in 2015 by the Council indicate the highest reported maximum concentration of use to be 80% in hair sprays.5 This product is believed to be solely used in spray products, like hair spray and spray deodorants. However, because this ingredient is a gas under all exposure conditions, inhalation is possible for all product types in which it is used. Hydrofluorocarbon 152a is not restricted from use as a cosmetic in any way under the rules governing cosmetic products in the European Union.6 Non-Cosmetic Hydrofluorocarbon 152a may be used as an aerosol propellant, a foam expansion agent, a refrigerant, and as a catalyst regenerator.3 TOXICOKINETICS Absorption, Distribution, Metabolism, and Excretion (ADME) Animal Inhalation Metabolites identified in urine collected for nuclear magnetic resonance (NMR) spectroscopy analysis from male CD rats exposed via inhalation to 3000 ppm Hydrofluorocarbon 152a (see Acute Toxicity for further study details) included fluoride ion and a trace of acetyl fluoride.7 No fluoroacetate was detected. The time at which the urine was collected after exposure was not identified in the study report. Human Inhalation The uptake, distribution, and elimination of Hydrofluorocarbon 152a were studied in male and female subjects.8,9 Six women and 4 men completed all exposure sessions (0, 200, and 1000 ppm test material), with one additional male exposed to 0 and 200 ppm, another male exposed to only 200 ppm, and another male exposed only to 0 ppm (n for 0 ppm = 12, n for 200 ppm = 12, and n for 1000 ppm = 10). Subjects were exposed for 2 h on three separate occasions to Hydrofluorocarbon 152a, and exposures were performed during light exercise on computer- controlled ergometer bicycles in an exposure chamber (20 m3) with a controlled climate. The concentration of the test material in the chamber was checked by gas chromatography (GC) at 5 minute intervals throughout the exposure sessions. Mixed exhaled air was collected once before the exposure, five times during the exposure, and seven times after the exposure. Pulmonary ventilation was recorded with an electric spirometer during every breath sampling period. Venous blood was collected from the brachial vein prior to exposure and at 3 h and 22 h after exposure for analysis of inflammatory markers, while arterialized capillary blood was collected from the subjects’ finger tips before, during, and after exposure. Urine was sampled once before exposure and at 2, 4, and 6 h after onset of exposure, as well as twice in the evening and once the following morning. The presence of Hydrofluorocarbon 152a in the blood and urine was analyzed by head-space GC. The urine was analyzed for fluoride with an ion selective electrode and for potential metabolites with NMR. In the blood, initial increases in Hydrofluorocarbon 152a were fast and average concentrations of 7.4 μM (for 200 ppm) and 34.3 μM (for 1000 ppm) were achieved within a few minutes of exposure. Within 4 h post- exposure, the concentration was less than 1% of the steady state level. Blood concentrations were below detection limits 22 h post-exposure. The area under the curve (AUC) of the test material in blood was 1042 μM min at 200 ppm and 4572 μM min at 1000 ppm, which indicated dose-proportional kinetics. No exposure-related effects were observed in inflammatory markers in the blood plasma. Total inhaled Hydrofluorocarbon 152a was approximately 20.6 and 99.6 mmol for the 200 and 1000 ppm exposures, respectively. Post-exposure decreases of the test material in exhaled air and urine were similar to that in blood. The AUCs of the test material in urine were 190 μM min for 200 ppm and 1271 μM min for 1000 ppm. After exposure to 200 ppm and 1000 ppm Hydrofluorocarbon 152a, about 0.004% and 0.009%, respectively, of the total amount inhaled was excreted in the urine within 23 h. About 20 μmol excess fluoride (0.013% of inhaled) was excreted in urine following the exposure to 1000 ppm test material when compared to the control. This was statistically significantly greater than the amount excreted in the urine of both the control and the 200 ppm exposed subjects (p=0.008) and remained significant elevated in the post hoc test (p<0.05). Fluoride excretion rate varied; however, it was statistically significantly higher in the first 2 urine samples after exposure to 1000 ppm test material when compared to the control subjects and subjects exposed to 200 ppm (p=0.0004). No fluorine-containing metabolites could be detected in the urine, indicating biotransformation of the test material in humans was very low.8,9 TOXICOLOGICAL STUDIES Acute Toxicity Studies 3,7,9 Acute oral and inhalation studies are summarized in Table 3. In rats, the lowest lethal oral dose (LDLO) reported for Hydrofluorocarbon 152a was greater than 1500 mg/kg, which was the highest dosage tested.3 However, this study was considered invalid by the Organization for Economic Co-operation and Development (OECD) because an unsuitable test system was used. The LC50 reported in a mouse inhalation study was 977,200 ppm. Cardiac arrhythmia was observed in dogs exposed for 5 min to 150,000 ppm Hydrofluorocarbon 152a in an inhalation study. Short-Term Toxicity Studies Inhalation In a short-term inhalation study of Hydrofluorocarbon 152a, 10 male ChR-CD rats were exposed to 100,000 ppm of the test material in air 6 h/day for 5 days/week for 2 weeks.3,9 Following the final exposure, 5 rats were killed for gross and histopathologic examination while the remaining rats were killed after a 14-day recovery period. Hematological, urine analytical, and biochemical indices were measured in all rats prior to being killed. During exposure to the test material, the rats appeared to be anesthetized, which was indicated by sleep and unresponsiveness to sound. No other adverse effects were observed. A slight increase in urinary fluoride was observed following the final exposure. In another short-term study, 8 albino rats (sex not provided) were exposed to 100,000 ppm Hydrofluoro- carbon 152a in air 16 h/day for 2 months.3,9 At the end of the exposure period, the animals were killed and examined for gross pathological changes.
Load more

Recommended publications
  • Plasma Contact System Activation Drives Anaphylaxis in Severe Mast Cell–Mediated Allergic Reactions
    Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions Anna Sala-Cunill, MD, PhD,a,b,c Jenny Bjorkqvist,€ MSc,c,d Riccardo Senter, MD,c,e Mar Guilarte, MD, PhD,a,b Victoria Cardona, MD, PhD,a,b Moises Labrador, MD, PhD,a,b Katrin F. Nickel, PhD,c,d,f Lynn Butler, PhD,c,d,f Olga Luengo, MD, PhD,a,b Parvin Kumar, MSc,c,d Linda Labberton, MSc,c,d Andy Long, PhD,f Antonio Di Gennaro, PhD,c,d Ellinor Kenne, PhD,c,d Anne Jams€ a,€ PhD,c,d Thorsten Krieger, MD,f Hartmut Schluter,€ PhD,f Tobias Fuchs, PhD,c,d,f Stefanie Flohr, PhD,g Ulrich Hassiepen, PhD,g Frederic Cumin, PhD,g Keith McCrae, MD,h Coen Maas, PhD,i Evi Stavrou, MD,j and Thomas Renne, MD, PhDc,d,f Barcelona, Spain, Stockholm, Sweden, Padua, Italy, Hamburg, Germany, Basel, Switzerland, Cleveland, Ohio, and Utrecht, The Netherlands Background: Anaphylaxis is an acute, potentially lethal, hypotension. Activated mast cells systemically released heparin, multisystem syndrome resulting from the sudden release of mast which provided a negatively charged surface for factor XII cell–derived mediators into the circulation. autoactivation. Activated factor XII generates plasma Objectives and Methods: We report here that a plasma protease kallikrein, which proteolyzes kininogen, leading to the cascade, the factor XII–driven contact system, critically liberation of bradykinin. We evaluated the contact system in contributes to the pathogenesis of anaphylaxis in both murine patients with anaphylaxis. In all 10 plasma samples models and human subjects. immunoblotting revealed activation of factor XII, plasma Results: Deficiency in or pharmacologic inhibition of factor XII, kallikrein, and kininogen during the acute phase of anaphylaxis plasma kallikrein, high-molecular-weight kininogen, or the but not at basal conditions or in healthy control subjects.
    [Show full text]
  • First Aid Management of Accidental Hypothermia and Cold Injuries - an Update of the Australian Resuscitation Council Guidelines
    First Aid Management of Accidental Hypothermia and Cold Injuries - an update of the Australian Resuscitation Council Guidelines Dr Rowena Christiansen ARC Representative Member Chair, Australian Ski Patrol Medical Advisory Committee All images are used solely for the purposes of education and information. Image credits may be found at the end of the presentation. 1 Affiliations • Medical Educator, University of Melbourne Medical • Chair, Associate Fellows Group, School Aerospace Medical Association • Director, Mars Society Australia • Board Member and SiG member, WADEM • Chair, Australian Ski Patrol Association Medical Advisory Committee • Inaugural Treasurer, Australasian Wilderness • Honorary Medical Officer, Mt Baw Baw Ski Patrol and Expedition Medicine Society (Victoria, Australia) • Member, Space Life Sciences Sub-Committee of • Representative Member, Australian Resuscitation Council the Australasian Society for Aerospace Medicine 2 Background • Australian Resuscitation Council (“ARC”) Guideline 9.3.3 “Hypothermia: First Aid Management” was published in February 2009; • Guideline 9.3.6 “Cold Injury” was published in March 2000; • A review of these Guidelines has been undertaken by the ARC First Aid task- force based on combination of a focused literature review and expert opinion (including from Australian surf life-saving and ski patrol organisations and the International Commission for Mountain Emergency Medicine (the Medical Commission of the International Commission on Alpine Rescue - “ICAR MEDCOM”); and • It is intended to publish the revised Guidelines as a jointly-badged product of the Australian and New Zealand Committee on Resuscitation (“ANZCOR”). 3 Defining the scope of the Guidelines • The scope of practice: • The ‘pre-hospital’ or ‘out-of-hospital’ setting. • Who does this guideline apply to? • This guideline applies to adult and child victims.
    [Show full text]
  • The Use of Radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor Deficiency
    Avances en Biomedicina ISSN: 2477-9369 ISSN: 2244-7881 [email protected] Universidad de los Andes Venezuela The use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Lara de la Rosa, María del Pilar; Conde Alcañiz, Amparo; Moreno Ramírez, David; Illescas Vacas, Ana; Guardia Martínez, Pedro The use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Avances en Biomedicina, vol. 7, no. 2, 2018 Universidad de los Andes, Venezuela Available in: https://www.redalyc.org/articulo.oa?id=331359393006 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative Casos Clínicos e use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Uso de radioterapia en Angioedema hereditario por déficit de C1 inhibidor tipo I María del Pilar Lara de la Rosa [email protected] University Hospital Virgen Macarena, España Amparo Conde Alcañiz University Hospital Virgen Macarena, España David Moreno Ramírez University Hospital Virgen Macarena, España Ana Illescas Vacas University Hospital Virgen Macarena, España Pedro Guardia Martínez University Hospital Virgen Macarena, España Avances en Biomedicina, vol. 7, no. 2, 2018 Universidad de los Andes, Venezuela Received: 27 February 2018 Accepted: 21 June 2018 Abstract: We present a clinical case of a 72 year old man with Hereditary Angioedema Type 1. It´s a rare, potentially fatal disease, especially due to causing episodes of Redalyc: https://www.redalyc.org/ laryngeal angioedema. He has a past medical history of lip squamous-cell skin cancer, articulo.oa?id=331359393006 which is currently relapsing, with lateral margins of the surgical resection affected requiring treatment with local radiotherapy.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]
  • Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview
    CrackCast Show Notes –Allergy and Anaphylaxis – October 2017 www.canadiem.org/crackcast Chapter 109 – Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview Key Points: 1. A history of sudden urticarial rash accompanied by respiratory difficulty, abdominal pain, or hypotension, strongly favors the diagnosis of anaphylaxis. 2. Epinephrine is the first-line treatment in patients with anaphylaxis: give it immediately. 3. There are no absolute contraindications to the use of epinephrine in the setting of anaphylaxis. 4. Antihistamines and corticosteroids are second- and third-line agents in the management of anaphylaxis and should not replace or precede epinephrine. 5. Consider prolonged observation or admission for patients who: a. Experience protracted anaphylaxis, hypotension, or airway involvement; b. Receive IV epinephrine or more than two doses of IM epinephrine; c. Or have poor outpatient social support. 6. Patients discharged after an anaphylactic event should be prescribed an EpiPen and instructed on its use. 7. Patients with refractory hypotension may require glucagon (receiving beta-blockage) or a continuous IV epinephrine infusion. 8. Non-histaminergic angioedema (non-allergic angioedema) does not typically respond to epinephrine and antihistamines. New drugs, including berinert, icatibant, ecallantide, and Ruconest have been approved for use in HAE. FFP has been used with varying success in HAE, ACID, and ACE inhibitor–induced angioedema. NOTE: ACID: acquired C1 esterase deficiency (ACED) Core Questions: 1. List the four types of Gell and Coombs classifications of immune reaction and give examples of each 2. List four etiologic agents causing anaphylaxis by immunologic mechanisms 3. List six mediators of anaphylaxis and their physiologic actions and clinical manifestations 4.
    [Show full text]
  • Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor
    J Am Board Fam Pract: first published as 10.3122/jabfm.10.5.370 on 1 September 1997. Downloaded from BRIEF REPORTS Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor Adriana]. Pavietic, MD Angioedema is an uncommon adverse effect of cyclobenzaprine, her angioedema was initially be­ angiotensin-converting enzyme (ACE) inhib­ lieved to be an allergic reaction to this drug, and itors. Its frequency ranges from 0.1 percent in pa­ it was discontinued. She was also given 125 mg of tients on captopril, lisinopril, and quinapril to 0.5 methylprednisolone intramuscularly. Her an­ percent in patients on benazepril. l Most cases are gioedema did not improve, and she returned to mild and occur within the first week of treat­ the clinic the following day. She was seen by an­ ment. 2-4 Recent reports indicate that late-onset other physician, who discontinued lisinopril, and angioedema might be more prevalent than ini­ her symptoms resolved within 24 hours. Mter her tially thought, and fatal cases have been de­ ACE inhibitor was discontinued, she experienced scribed.5-11 Many physicians are not familiar with more symptoms and an increased frequency of late-onset angioedema associated with ACE in­ palpitations, but she had no change in exercise hibitors, and a delayed diagnosis can have poten­ tolerance. A cardiologist was consulted, who pre­ tially serious consequences.5,8-II scribed the angiotensin II receptor antagonist losartan (initially at dosages of 25 mg/d and then Case Report 50 mg/d). The patient was advised to report any A 57-year-old African-American woman with symptoms or signs of angioedema immediately copyright.
    [Show full text]
  • Angioedema, a Life-Threatening Adverse Reaction to ACE-Inhibitors
    DOI: 10.2478/rjr-2019-0023 Romanian Journal of Rhinology, Volume 9, No. 36, October - December 2019 LITERATURE REVIEW Angioedema, a life-threatening adverse reaction to ACE-inhibitors Ramona Ungureanu1, Elena Madalan2 1ENT Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Bucharest, Romania 2Allergology Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Romania ABSTRACT Angioedema with life-threatening site is one of the most impressive and serious reasons for presenting to the ENT doctor. Among different causes (tumors, local infections, allergy reactions), an important cause is the side-effect of the angiotensin converting enzyme (ACE) inhibitors drugs. ACE-inhibitors-induced angioedema is described to be the most frequent form of bradykinin- mediated angioedema presented in emergency and also one of the most encountered drug-induced angioedema. The edema can involve one or more areas of the head and neck region, the most affected being the face, the lips, the tongue, followed by the larynx, when it may determine respiratory distress and even death. There are no specific diagnosis tests available and the positive diagnosis of ACE-inhibitors-induced angioedema is an exclusion diagnosis. The authors performed a review of the most important characteristics of the angioedema caused by ACE-inhibitors and present their experience emphasizing the diagnostic algorithm. KEYWORDS: angioedema, ACE-inhibitors, hereditary angioedema, bradykinin, histamine. INTRODUCTION with secondary local extravasation of plasma and tissue swelling5,6. Angioedema (AE) is a life-threatening condition Based on this pathomechanism, the classification presented as an asymmetric, localised, well-demar- of angioedema comprises three major types: 1). cated swelling1, located in the mucosal and submu- bradykinin-mediated – with either complement C1 cosal layers of the upper respiratory airways.
    [Show full text]
  • Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2
    Rovenský et al. J Rheum Dis Treat 2016, 2:043 Volume 2 | Issue 4 Journal of ISSN: 2469-5726 Rheumatic Diseases and Treatment Review Article: Open Access Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2 1National Institute of Rheumatic Diseases, Piešťany, Slovak Republic 2Department of Rheumatology and Rehabilitation, Thomayer Hospital, Prague 4, Czech Republic *Corresponding author: Jozef Rovenský, National Institute of Rheumatic Diseases, Piešťany, Slovak Republic, E-mail: [email protected] of patients; in the systemic vasculitis subgroup survival is similar to Abstract that of patients with polyarteritis (up to about five years in 45% of Relapsing polychondritis (RP) is a rare immune-mediated disease patients). The period of survival is reduced mainly due to infection that may affect multiple organs. It is characterised by recurrent and respiratory compromise. episodes of inflammation of cartilaginous structures and other connective tissues, rich in glycosaminoglycan. Clinical symptoms Etiology and Pathogenesis concentrate in auricles, nose, larynx, upper airways, joints, heart, blood vessels, inner ear, cornea and sclera. The most prominent RP manifestation is inflammation of cartilaginous structures resulting in their destruction and fibrosis. Diagnosis of the disease is based on the Minnesota diagnostic criteria of 1986 and RP has to be suspected when the inflammatory It is characterised by a dense inflammatory infiltrate, composed bouts involve at least two of the typical sites - auricular, nasal, of neutrophil leukocytes, lymphocytes, macrophages and plasma laryngo-tracheal or one of the typical sites and two other - ocular, cells. At the onset, the disease affects only the perichondral area, statoacoustic disturbances (hearing loss and/or vertigo) and the inflammatory process gradually leads to loss of proteoglycans, arthritis.
    [Show full text]
  • Management of Food Allergies
    MANAGEMENT OF FOOD ALLERGIES Federal Bureau of Prisons Clinical Guidance NOVEMBER 2017 Clinical guidance documents are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp Federal Bureau of Prisons Management of Food Allergies Clinical Guidance November 2017 WHAT’S NEW IN THIS DOCUMENT? Several updates have been made since the September 2012 version of this document, including the following: • The order of the Appendices has been changed somewhat. Please see the Table of Contents on the next page. • Pharmacologic management of anaphylactic food allergies should focus on the use of epinephrine, usually via an auto-injector that is on the inmate’s person at all times. Epinephrine auto-injectors are processed as a pill-line item. Inmates will present the device at pill line at least once daily to verify that the seal is intact and has not been manipulated. • The current Appendix 3, Emergency Treatment of Anaphylaxis (Outpatient), replaces the former Appendix 5, Pharmacological Treatment of Anaphylaxis. The table has been updated to include more specific information about repeating epinephrine injections, as well as revisions to the information about additional and optional therapies.
    [Show full text]
  • Angioedema in the Emergency Department: a Practical Guide to Differential Diagnosis and Management Jonathan A
    Bernstein et al. International Journal of Emergency Medicine (2017) 10:15 International Journal of DOI 10.1186/s12245-017-0141-z Emergency Medicine REVIEW Open Access Angioedema in the emergency department: a practical guide to differential diagnosis and management Jonathan A. Bernstein1*, Paolo Cremonesi2, Thomas K. Hoffmann3 and John Hollingsworth4 Abstract Background: Angioedema is a common presentation in the emergency department (ED). Airway angioedema can be fatal; therefore, prompt diagnosis and correct treatment are vital. Objective of the review: Based on the findings of two expert panels attended by international experts in angioedema and emergency medicine, this review aims to provide practical guidance on the diagnosis, differentiation, and management of histamine- and bradykinin-mediated angioedema in the ED. Review: The most common pathophysiology underlying angioedema is mediated by histamine; however, ED staff must be alert for the less common bradykinin-mediated forms of angioedema. Crucially, bradykinin-mediated angioedema does not respond to the same treatment as histamine-mediated angioedema. Bradykinin-mediated angioedema can result from many causes, including hereditary defects in C1 esterase inhibitor (C1-INH), side effects of angiotensin-converting enzyme inhibitors (ACEis), or acquired deficiency in C1-INH. The increased use of ACEis in recent decades has resulted in more frequent encounters with ACEi-induced angioedema in the ED; however, surveys have shown that many ED staff may not know how to recognize or manage bradykinin-mediated angioedema, and hospitals may not have specific medications or protocols in place. Conclusion: ED physicians must be aware of the different pathophysiologic pathways that lead to angioedema in order to efficiently and effectively manage these potentially fatal conditions.
    [Show full text]
  • Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema
    Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema Abduljabar A. Theyab, MD; David S. Lee, MD; Amor Khachemoune, MD Angiotensin-converting enzyme (ACE) inhibitors the cumulative risk for developing angioedema is frequently are prescribed for the management of believed to be higher due to the long-term nature cardiovascular disorders. In addition to their ther- of treatment with ACE inhibitors and the fact that apeutic potential, ACE inhibitors are associated angioedema can occur at any point during therapy.6 with numerous adverse effects, some of which More than 3 decades after the first description of may be lethal. Angioedema is an uncommon but ACE inhibitor–induced angioedema, more is now serious acute event that may affect any individual understood about its underlying pathophysiology and taking an ACE inhibitor. This review outlines the variable clinical manifestations. In this article, we advances in our understanding of the pathogen- review the historical context of this phenomenon, esis, clinical presentation, and management of proposed molecular mechanisms, and clinical con- this medical emergency. siderations in the diagnosis and management of this Cutis. 2013;91:30-35. potentially fatal entity (Table). CUTISHistory ngiotensin-converting enzyme (ACE) inhibi- Angioedema was first described in the literature by tors are among the most commonly pre- Milton7 in 1876. The term angioneurotic angioedema scribed drugs in modern medicine with more was coined in 1882 by Quincke.8 Almost a century A 1 9 than 40 million patients using them. Numerous later, Wilkin et al characterized the association of ACE inhibitors are currently available (eg, captopril, angioedema with ACE inhibitor use in 1980 in a case benazepril, fosinopril, enalapril, zofenopril, ramipril, series involving 22 patients who received captopril, quinaprilDo hydrochloride, perindopril Not erbumine, lisino- which atCopy the time was a newly marketed antihyper- pril), differing primarily in their duration of action tensive agent.
    [Show full text]
  • Inhaling Difluoroethane Computer Cleaner Resulting in Acute Kidney Injury and Chronic Kidney Disease
    Hindawi Case Reports in Nephrology Volume 2018, Article ID 4627890, 3 pages https://doi.org/10.1155/2018/4627890 Case Report Inhaling Difluoroethane Computer Cleaner Resulting in Acute Kidney Injury and Chronic Kidney Disease Kristen Calhoun,1 Laura Wattenbarger ,1 Ethan Burns ,2 Courtney Hatcher ,2 Amol Patel,2 Manjulatha Badam ,2 and Abdul-Jabbar Khan2 1 Texas A&M College of Medicine, Te Methodist Hospital at Houston, 6565 Fannin Street, West Pavilion, Houston, TX 77030, USA 2HoustonMethodistHospital,6550FanninStreet,Suite1101,SmithTower,Houston,TX77030,USA Correspondence should be addressed to Ethan Burns; [email protected] Received 29 March 2018; Accepted 16 April 2018; Published 7 June 2018 Academic Editor: Ze’ev Korzets Copyright © 2018 Kristen Calhoun et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Difuoroethane is the active ingredient in various computer cleaners and is increasingly abused by teenagers due to its ease of access, quick onset of euphoric efects, and lack of detectability on current urine drug screens. Te substance has detrimental efects on various organ systems; however, its efects on the kidneys remain largely unreported. Te following case report adds new information to the developing topic of acute kidney injury in patients abusing difuoroethane inhalants. In addition, it is one of the frst to show a possible relationship between prolonged difuoroethane abuse and the development of chronic kidney disease in the absence of other predisposing risk factors. 1. Introduction police afer a violent outburst following prolonged DFE abuse during a suicide attempt.
    [Show full text]